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This report describes the organization and results of the 
European Cooperative Study Group trial of intravenous 
recombinant tissue-type plasminugen activator (r&PA) plus 
conservative therapy versus intravenous r&PA plus imme- 
diate intervention (coronary angiography with a view to 
angioplasty) in patients with acute myocardial infarction. 
One hundred eighty-four patients were altofated to nonin- 
vasive treatment and 183 to an invasive/intervention policy. 
Immediate angioplasty was attempted in IQ patients (YZ%) 
of the latter group. The trial was terminated after a data 
review hy the ethical monitoring committee showed no 
benetit in the “invasive” group in terms of enzymatic 
infarct size or  left ventricular function, and a trend (al- 
though not statistically significant) toward increased mor- 
tality io tP: intervention group. Analysis of coronary 
patency and residual stenosis at the time of discharge 
showed no difference in patency rate, but less residual 
stenosis in the intervention group. 
The study differed from the Thrombolysis and Angio- 
plasty in Myocardial Infarction (TAMI) and the Throm- 
bolysis in Myocardiat Infarction Phase-IIB (TIMI-IIB) tri- 
als in that the philosophy of intervention to produce the 
earliest and most complete reperfusion resulted in a high 
incidence of angioplasty and the initiation of one-third of 
the angioplasty procedures in vessels not yet reperfuscd. 
The reasons for the failure of this philosophy to show 
benefit are uncertain, but may include an increased risk of 
reocclusion after angioplasty or  roperfusion damage, or  
both. 
(J Am Coil CardiolIF88~1L~2OA-3A) 
The “first phase” of clinical trials of recombinant human 
tissue-type plasminogen activator (rt-PA) comprised the 
Thrombolysis in Myocardial Infarction (TIMI) trial (phase I) 
(I) in the United States, and the two linked trials (2,3) of the 
European Cooperative Study Group (ECSG) in Europe. 
These clearly established that intravenous &PA was an 
effective agent for restoring coronary vessel patency, and 
compared well with a “standard” regimen of 1.5 million U of 
streptokinase. Several questions were left unanswered, how- 
ever, one of the most pressing being whether a “nonin- 
vasive” approach using intravenous rt-PA followed by anti- 
coagulation and perhaps “symptom-led” intervention was 
adequate, or whether a policy of deliberate ea, ly angiogra- 
phy and elective angioplasty of severe residual stenosis 
would be better. 
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the observations of the Rotterdam group (4)  and others that 
significant residual stenosis remained after thrombolysis in 
approximately 70% of infarct-related vessels; 2) the correla- 
tion by Harrison et al. (5) of severe residual stenosis with a 
high risk of early reocclusion; and 3) d worrisome high rate 
of early reocclusion after r&PA thrombolysis in the TIM1 
study (6). There was also experimental support from the 
work of Erbel et al. (7), who showed benefit from early 
angioplasty in a randomized trial of patients treated with 
streptokinase, and from the experiences in the Netherlands 
Interuniversity Study Group trial (8). in which the initial 
policy of intracoronary administration of streptokinase was 
changed halfway though the trial to a policy of intravenous 
administration of streplokinase followed by immediate 
angioplasty with a view to intervention. Analysis of patients 
treated by the two methods appeared to show better results 
in patients given intravenous streptokinase followed by 
angioplasty. 
Conversely, a treatment strategy that did not require 
urgent angiography and angioplasty would greatly ease the 
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logistic problems of providing large-scale access to throm- 
bolysis. The European Cooperative Study Group (ECSG). 
therefore, designed and carried out a trtal comparing an 
“invasive” and a “noninvasive” treatment strategy after 
thrombolysis with intravenous rt-PA in acute myocardial 
infarction. The initial definitive report of this trial recently 
appeared in Lancer (9). 
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Figure I. Patrncy of infarct related-vessel as a function of the time 
between start of mfukn and angiognphic vl\ualization. 
The trial was carried ou: in X centers (Aachen. Barce- 
lona, Berlin. Brussc!~. Geneva, Ldle, Munich. Rotterdam. 
Paris and Tours) with previous extensive experience m 
coronary angioplasty, including angioplasty in acute myo- 
cardial infarction. Entry criteria were similar to those of the 
orevious ECSG trials 12.3). Brieflv, these criteria were che\t 
Assessmenr of results. The primary end points of the 
study were enzymatic infarct size c&mated from Ferial 
measuremtnts of plasma hydroxybutyrate dehydrogenase 
activity (IO) and left ventricular function assessed from left 
ventricular cineangiograms performed before hospital dis- 
charge. Enryme estima!‘ons and angiographic measure- 
mentc were Jone centrally. Coronary angiography was done 
at the time of angioplasty in patients randomized to invasive 
management. an3 before discharge in all patients. Coronary 
arteriogram\ ae:e centrally assessed for perfusion of the 
infarct-related vessel with use of the TIM1 criteria, and for 
the distribution a?d degree of coronary stenosis with u\c of 
the semiquantitative ECSG criteria (2). 
Results 
Clinical features. Treatment groups were evenly matched 
for age. gender. proportion of anterior myocardial infarc- 
tions and blood pressure at presentation. More of the 184 
patients in the noninvasive group had features of mild heart 
failure (46 versus 36). but more of the I83 patients in the 
invasive group had severe heart failure (7 versus I). 
Coronary arteriography and angiopiasty. In the invasive 
group. I80 of the 183 patients underwent angiography from 
20 to I20 mm after the start of the rt-PA infusion. Angiog- 
raphy revealed that IO8 infarct-related vessels were perfused 
(TIMI grade 2 or  3). and the proportion of perfused vessels 
was related to the elapsed time since the start of thrombo- 
lytic therapy (Fig. I). Seventy-two patients had a totally 
occluded (n = 42)  or  partially perfused (TIM! grade I. n  = 
30)  vessel. Coronary angioplasty was attempted in 168 
patients in the invasive group. but waq not attempted in 12 
for reason\ given in Table I. At the end of the angioplasty 
procedure, the infarct-related vessel was patent in 57 of the 
72 patient? who initially had an occluded vessel, but it had 
rroccluded in 3 who initially had a patent vessel (Fig. 21: one 
hundred three of I68 patients had residual stenosis <SO% 
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Table 1. Angtographic Fmdings in the Intervention Group 
No. of pdlvmr rtindomzcd to mlervenlmn IX3 
No angwaphy 3 II dted from shock. I 
wahdrew consent. I 
equlpmenl fadure) 
Vessel occluded at early 
PTCA performed 
Vessel patent a, early angwgaphy 108 
FfCA performed 96 IBWI 
PTCA not oerformed I2 
Lefl mam eauivalenl dwzase 
Severe three vessel dtrease 
Old occl~s,~n wlh retrofilhng 
Infarct-related vessel unkn& I 
-  
PKA = percutaneous lranslummal coronary ang~oplasly 
vessel diameter after annioolastv. The number of balloon -. . 
inflations ranged from I IO 15; the median inflation time was 
180 s. Transient reocclusion during angioplasty occurred in 
26 patients. 
&niral course. The clinical course after admission was 
eenerallv more favorable in the oatients in the noninvasive 
iroup, who had less recurrent ischemia in the first 24 h (3 
;ers;s 17%). less hypotension (9 versus 31%). fewer bleed- 
inc. comolications (23 versus 41%) and less ventricular fibril- 
IaZon (j versus I I%) than did those in the invasive group. 
There was no difference in the rate of ventricular tachycardia 
(28 versus 30%). recurrent ischemia after 24 h (30 versus 
28%) or late reinfarction (IO versus 7%). At 3 month fol- 
low-up study, there had been 6 deaths in the noninvasive 
group and I5 in the invasive group (,$ = 3.17; 0.1 > p > 
0.05). Only II of the patients with a fatal outcome in the 
invasive group actually had coronary angioplasty and it had 
been technically successful in 7. 
Infarct size and ventricular function. Enzvmatic infarct 
size estimations performed in 359 of the 367 patients showed 
no significant difference between the invasivk group (median 
706 U/liter; 90% range, I IS to 1,914) and the noninvasive 
group (median 665 Miter; 90% range, 32 to 2,022). 
Glohol /eft ventricular jirncfion was estimated from 291 
left ventricuiar angiograms of adequate quality performed IO 
to 22 days after admission. There was no significant differ- 
Figure 2. Fate of infarct-related vessels in I80 patients allocated to 
the “intervention” arm of the study. FICA = percutaneous trans- 
luminal coronary angioplasly. 
Table 2. Perfusion Grade (TIMI criteria) and Stenosis Grade 
(ECSG) of Infarct-Rrlated Vessels Before and ARer Angioplasly 
in Intervention (inva,&e) Group and a1 Discharge in Both 
intervention and Corlservalive (noninvasive) Management Groups 
Early 
Angmgraphy Pre-PTCA Post F’TCA 
Stenosis 
Grades 0 and I 9 103 
Grade 2 51 41 
Grade 3 48 II 
Grade 4 30 7 
late 
Angioaraphy 
II0 IO I4 days) 
Stenosis 
Grades 0 and I 106 25 
Grade 2 25 84 
Grade 3 4 28 
Grades 4 and 5 23 20 
No data ‘) I6 
P.XfUSiO!l 
Grade 3 130 138 
Grade 2 3 I2 
Grddep 0 and I 26 18 
Post = after: Pre = before: PTCA = percutaneous lransluminal coronary 
angioplasly 
ence in left ventricular ejection fraction between the nonin- 
vasive group (median 51%; 90% range, 29 to 65%) and the 
invasive group (median 51%; 90% range, 31 to 66%). 
Residual coronary stenosis. Analysis of the residual ste- 
nosis in the infarct-related vessel showed considerable im- 
provement when the postangioplasty arteriogram was com- 
pared with the preangioplasty study, and in the predischarge 
angiograms the patients allocated to the invasive strategy 
had less residual stenosis, hut a higher incidence of totally 
occluded infarct-related vessels (Table 2). 
Discussion 
Role of immediate coronary arteriography and angioplasty. 
These results do not support the hypothesis that the use CT 
immediate coronary angiography and angioplasty after early 
intravenous thro1nbolysis improves the outcome in acute 
myocardial infarction. Is this an encouraging or discouraging 
result? It is encouraging in that it is becoming increasingly 
clear that intravenous thrombolytic therapy can significantly 
improve the survival rate in myocardial infarction even 
without immediate access to angiographic or interventional 
facilities (I 1.12). Conversely, it is discouraging in that the 
close correlation so far observed between the results of 
clinical trials and !aboratory studies appears (but perhaps 
only appears) to have been broken. 
The fortuitous excess in the number of patients with 
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cardiogenic shock allocated to the invasive strategy group 
may have contributed to the excess number of deaths m that 
group, but these numbers were too small to have had much 
impact on overall infarct size or  left ventricular function 
results. The high proportion of patients m whom angtopla\ty 
was attempted in the invasive strategy group mu\t be vtewed 
in the context of the underlying phdosophy. based on 
laboratory studies. that maximal myocardial salvage would 
be achieved by the earliest and most complete myocardial 
reperfusion. It is important to appreciate that tht5 i\ a  totally 
different philosophy from that of the TAM1 and TIM-IIB 
trials, where the question was, having achieved coronary 
vessel patency, how best to maintain IL Nearly half (4%) of 
the immediate angioplasty procedures m the present study 
were performed on vessels thit had not yet been reperfu\ed. 
and the early patency rate achtcved (79’2) was COIIpimbk 
with that in trials of angioplasty ,‘ersus streptokinase t 13). 
This philosophy also accounts for tb- high angioplasty rate 
in the “intervention” arm; however. .ngioplasty was MI 
performed in the presence of left main or  left mam coronary 
equivalent stenosis (Table I). The relatively high reocclusion 
rate, whether of transient or  permanent reocclusion. ts 
worrisome, but is again in accordance with previous angio- 
plasty results in the presence of intracoronary thrombus and 
a potentially unstable intimal flap. It wds not possible io 
predict the rate of reocclusion from the angiographic appear-  
ances either before or  immediately after angioplasty. It may 
be that the relative lack of fibrinogen depletion with &PA 
therapy as opposed to streptokinase !herapy encourages 
rethrombosis, but the patients were all well anticoagulated 
with heparin and in the majority of patients angioplasty was 
performed in the presence of a continuous r&PA infusion. 
Study implications. Future developments in coronary 
angioplasty and, in particular, the use of very effective 
anticoagulants and platelet antiaggregants, such as monoclo- 
nal antibodies to the glycoprotein llallllb platelet-adhesion 
molecules, may require reexamination of the problem. An- 
other possibility is that reperfusion injury, frequently dis- 
cussed in the context of animal models but so far difficutt to 
verify clinically, became manifest as a result of earlier and 
more abrupt reperfusion than most trials have so far man- 
aged to achieve. It may be that we need to pay more 
attention to the “total body stress” of early angiography and 
a prolonged angioplasty procedure. particularly because 
high plasma catecholamine concentrations and increased 
endorphin release are correlated with an impaired prognosis 
in myocardial infarction. 
At present, our  own approach to thrombolytic therapy is 
to give intravenous thrombolysis as early as possible, per-  
form early Intervention only when it is called for by persist- 
ent or  recurrent chest pain and consider delayed angioplasty 
or  coronary artery bypa\> grafting on the basis of late 
angtographtc and exercise te% result\. There is general 
‘ccepmnce that patients who have a coronary artery that 
fall\ to reperfu\e after thrombolytic therapy have a poor 
progno\t\. It would be an enormous help to be able to 
tdenttfy these patients so as to iutervene early but, paradox- 
ically. by the ttme they can be tdentttied by present tech- 
mque\. the opportunity to inlervenc is likely to have passed. 
New techmque\ to monitor the efhcacy and speed of reper-  
fu\ton wtll be very welcome. 
References 
I  The I’IMI Study Group. The Thromholyw I ”  \lyoc.~rd~~l Inlrcl~on 
I rtbut Study u Eqd J #ed 19K5.312 932-6 
? Ver~tr.tele M. Bernard R .  Bory Y .  et dl. Randomwed indl of mtrwenow 
recnmhmmt true type plasmmogeo xtwoor verwc mtr:wenooc strep- 
Iokm.,\r m .u,:e myocardlal mfarct~on. Lance1 19X5.1 X42-7 
1 Vcntrdcte I1 Rlufeld W. Brewer RW. et dl Double blmd randomiced 
trul of mtr.wmoo\ recombmdnt lwoe type plrwxnogen acnv,oor verws 
placeho m . ILUIC myowdlal mfxcl~on Ldncet 19X5.2 96-9 
5 Hrrrnoo DG Ferpwon DW. Colhn5 S M .  et I I .  Relhromboclr df!cr 
repcrfuu\~on wlh slreptokmwe: onportacce of ~eornelry of md;wdu<d 
lewmr C~rculacwn 19X4:69 9914 
6 Wdbrms DO Borer J. Bnonwald E .  et at lntrdvenouc recombmrnt 
hwe !ype pl.nmmogen actwator m pawntf wdh dcot~ myocardut 
mf.~rc!ton d repan from the NHLBI  Thrombolyw m M,ncard!al tnfsc- 
bon wd C~rculat,on 19X6373:33&46 
7 Erhel R .  Pop T. Hennch? K-J.  et dl Percul;meoo\ lr.mslononal coronrry 
mg~oplzly dfler lhrombolyllc therapy d prospectwe conlrolled random. 
rued trrcl J Am Coil Cardml 1986:X 485-95. 
X  Serruy~ PW. SIrnoon ML. Suryapranata H .  et al. Prescrwl~on of global 
dnd region I I  Is+1 vemrndar funcuon after early Ibrombolysn m xote 
myocardlal mf.lrcllon. J Am Coil Cardlol 19%6.77?9-4? 
9 Snmoons ML. Arnold A E R .  Betnu A .  et aI Thrombolyw wh bwuc 
plr\mmogen dctwdor m acule myocardial mfarcl~on: no dddmonal hen- 
elit from ammedlate percolon~ous dng~opl.wy La~cet 19XS.l’197-!O?. 
IO  uo der Lur\e A .  Hermens WT. Hollaar L. et dl Anewment of 
myocadul damage m pahenl? with dcote mvocardlal wfxct~on hy TendI 
mea\uremenl\ oi rerun alpha-hydroxybutyrle dehydrogerwe level5 
4m He,ln J 11184:107:?48-60 
I  I  Groppo ltalwno per lo Studio dela Slreptochmasa nel’lnbno Mweardxo 
( G I S S I ) .  Ekcwene~~ of m~wvenooc thrombolytlc lreatment m dcoie 
myocdrdlrl mfarcoon. Lancet 191.1:397-u)l. 
I? A I M S  Trval Study Group. EtTect of mtravenow A P S A C  on monahly after 
xute myocardial infarctiaw prelimmdry repon of d placebo coolrolled 
lrldl Lancel 1988:1,545-9. 
I3 O’Nedl WW. Timmls C C .  Boorddlon P D .  et dl. A  prospectwe mndom- 
ued cbmc.d !nal of mfncoronary \rreptokmase V C R U I  coronary dngw- 
platy for ,xole myocardial mfarci~on. N  En&l J Med 1986:31JR1?4 
